In this issue: Knock on effects of the Valsartan recall, the future of...
Roche reports positive Phase I/II data for entrectinib
Roche has reported that its investigational personalised medicine entrectinib shrank tumours in the Phase I/II STARTRK-NG clinical trial involving children and adolescents with recurrent or refractory solid tumours.
Pfizer’s abrocitinib meets goals in atopic dermatitis trial
Pfizer has reported positive top-line data from a Phase III clinical trial of its abrocitinib (PF-04965842), which met the primary and key secondary endpoints in moderate to severe atopic dermatitis (AD) patients aged 12 and older.
Minerva’s seltorexant improves depression symptoms in trial
Biopharmaceutical company Minerva Neurosciences has reported positive data from the Phase IIb clinical trial of seltorexant (MIN-202) as an adjunct to antidepressants in adults suffering from major depressive disorder (MDD).
Alzheimer’s consortium in US to trial two Eisai drugs
The Alzheimer's Clinical Trials Consortium (ACTC) in the US has partnered with Eisai to assess two of the Japanese pharmaceutical company’s drug candidates in clinical studies.
NIH’s LATITUDE trial to study long-acting HIV regimen
A new National Institutes of Health (NIH)-funded clinical trial has been started to assess a long-acting antiretroviral therapy (ART) for the treatment of people living with HIV.
Daiichi Sankyo-AstraZeneca’s breast cancer therapy clears trial
Daiichi Sankyo and AstraZeneca have reported positive findings from the Phase II DESTINY-Breast01 clinical trial of trastuzumab deruxtecan (DS-8201).
Merck’s V114 yields positive data in pneumococcal disease
Merck Sharp & Dohme has reported positive results from the Phase II clinical trial of its investigational 15-valent pneumococcal conjugate vaccine, V114.
Merck’s Belsomra achieves Phase III efficacy endpoints for insomnia
Merck Sharp & Dohme has reported that a Phase III clinical trial of Belsomra (suvorexant) C-IV has met the primary and secondary efficacy endpoints for the treatment of insomnia in patients with mild-to-moderate Alzheimer’s disease dementia.
AstraZeneca’s Calquence Ascend trial meets primary endpoint
British-Swedish pharmaceutical and biopharmaceutical company AstraZeneca has announced that the Phase III Ascend trial of Calquence (acalabrutinib) in previously-treated patients with chronic lymphocytic leukaemia (CLL) has met the primary endpoint.
Actinogen’s Xanamem fails to improve cognition in Phase II study
Actinogen Medical has reported initial results from the Phase II XanADu clinical trial, saying that 10mg Xanamem failed to improve cognition in patients with mild Alzheimer’s disease.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.